AdiStem Ltd. is a biotechnology company which discovers and develops new methods and apparatus to assist clinicians in using autologous blood and adult adipose-derived stem cells to address serious disease conditions, orthopedic applications, and to assist in particular cosmetic and plastic surgery procedures.

AdiStem owns proprietary technologies for stem cell administration that are shared with qualified medical practitioners through instructional courses, workshops and seminars. Due to its clinician and hospital relationships and collaborative efforts with medical institutions, AdiStem believes it is now a leading provider of autologous adipose-derived adult stem cell products and procedures.

There are now clinicians in the USA, Canada, Greece, South Africa, India, China, Saudi Arabia, Korea, Egypt, Turkey, Jordan, Philippines, Thailand, Malaysia, Mexico, Peru and Brazil who currently use some aspect of AdiStem technology in the treatment of patients and in further research on diseases.

Adipose-Derived Stem Cell Activation
AdiStem Ltd. has a proprietary technology for extracting and activating adult stem cells.
Adult Stem Cells (ASCs), otherwise also referred to as tissue-specific (multipotent) stem cells, have been shown – under specific suitable conditions – to generate a variety of different cell types including cell types of a different germ-layer of origin. This phenomenon is referred to as stem cell transdifferentiation or plasticity. The specific suitable conditions under which this transdifferentiation is induced is achieved by the modification of the culture medium in vitro, or by transplanting the stem cells into an organ, the tissue type of which is different to the one from which they were isolated. However, the exact mechanism of this transdifferentiation is still under debate.